Anti-Interleukin-6Ralpha/CD126 Chimeric Monoclonal Antibody (Clone rhPM-1 (Tocilizumab))

Interleukin-6Ralpha (IL-6Ralpha), also known as CD126, is a type I cytokine receptor. It is composed of an immunoglobulin-like domain, a cytokine-binding domain, a transmembrane domain, and a cytoplasmic domain and forms a heteromeric complex with IL-6 and gp130, which is the signal transducing subunit of the IL-6R that primarily acts through the JAK/STAT3 pathway. IL-6Ralpha is expressed in hepatocytes and monocytes and is localized to the plasma membrane but also exists as a soluble form (sIL-6Ralpha) that is primarily generated via proteolytic cleavage of membrane-bound IL-6Ralpha, but can also be formed via alternative splicing. Binding of IL-6 to membrane-bound IL-6Ralpha, known as classical signaling, upregulates the synthesis of acute phase proteins, induces lipolysis in the liver, and induces the differentiation of T and B cells and is primarily anti-inflammatory. Trans-signaling consists of IL-6 binding to sIL-6R, which has various pro-inflammatory effects. Knockdown of IL6R increases sensitivity to tamoxifen in breast cancer cells. Formulations containing chimeric anti-IL-6Ralpha monoclonal antibodies have been used in the treatment of rheumatoid arthritis, idiopathic arthritis, giant cell arteritis, cytokine release syndrome, and COVID-19. Cayman's Interleukin-6Ralpha/CD126 Chimeric Monoclonal Antibody (Clone rhPM-1 (Tocilizumab)) was produced recombinantly from the original rhPM-1 antibody and can be used for ELISA. The rhPM-1 antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions.Synonyms: gp80, IL6RA, Interleukin-6 Receptor Subunit alpha, Membrane Glycoprotein 80. Immunogen: Recombinant human IL-6Ralpha. Clone Designation: rhPM-1 (Tocilizumab). Formulation: (Request formulation change), 200 µg of protein A-affinity purified monoclonal antibody. Storage Buffer: PBS with 0.02% ProClin(TM) 300. Host: Chimeric Monoclonal Antibody. Isotype: IgG1?. Applications: ELISA. Cross Reactivity: (+) IL-6Ralpha, (+) sIL-6Ralpha. UniProt Accession #: P08887.